I n 1987, the federal Food and Drug Administration (FDA) approved 23 new drugs for marketing in the United States, 16 of which were approved in December, 1987 . The occupational health nurse may not be exposed to all 23 newly approved drugs, since several are hospital oriented or are only indicated for diagnostic purposes (see Table) . However, the other medications may be used by employees in the workplace.
This article will provide pertinent information for the occupational health nurse on the newest anticholinergic drug, a new bronchodilator, antihypertensive drugs, agents that lower blood cholesterol, antibacterial agents, and anti-inflammatory drugs.
IPRATROPIUM BROMIDE
Ipratropium bromide (Atrovent) is an atropine-derived, orally inhaled drug used in the treatment of chronic obstructive pulmonary disease (COPD). When inhaled, its anticholinergic action remains localized in the lungs. Therefore, adverse sys-temic effects associated with anticholinergic therapy usually do not occur when the recommended dosage is used (eg, dry mouth, blurry vision, urinary retention, and constipation).
Ipratropium produces bronchodilation by two mechanisms. It inhibits the release of cyclic guanosine monophosphate (c-GMP), thereby inhibiting contraction of bronchial smooth muscle and constriction of bronchial airways. It also blocks the action of acetylcholine at the receptor site.
Ipratropium is tolerated well in most individuals. Dry mouth (2.4%) and cough (5%) have been infrequently reported. If accidentally sprayed into the eyes, blurred vision could result. The recommended dosage is two puffs four times daily, up to 12 puffs in a 24 hour period. There are no apparent drug interactions.
Ipratropium represents a therapeutic advance in the treatment of COPD since people who cannot tolerate the adverse effects of sympathomimetic amines-bronchodilators have an alternate drug to treat their disease. It may also prove to be effective for asthmatics, and in combination with other drugs for COPD (Abramowicz, 1987c; FDC Reports, 1988; Kastrup, 1988) .
GUANFACINE HYDROCHLORIDE
Guanfacine (Tenex) is a centrally acting alpha-2 adrenergic receptor agonist taken orally in tablet form to treat hypertension. It stimulates alpha-2 adrenergic receptors in the brain that reduce sympathetic nerve impulses from the vasomotor center to the heart and blood vessels, resulting in a decreased heart rate and reduced peripheral vascular resistance.
Cardiac output remains unchanged.
The drug should be used with thiazide diuretics, not alone. It is indicated for the management of hypertension in people using thiazide diuretics who have not accomplished their therapeutic goal.
The initial dose is 1 mg daily for those who have been taking thiazide diuretics. If control is not accomplished after three to four weeks, the dose may be increased up to 3 mg daily. Guanfacine should be taken at bedtime to minimize somnolence.
Guanfacine should not be discontinued abruptly due to occurrence of rebound hypertension within two to four days. Adverse reactions include dry mouth, sedation, somnolence, fatigue, weakness, constipation, and impotence. These effects, although common, are usually mild and decrease over time. When guanfacine is given with central nervous system depressants, increased sedation may occur.
Employees should be aware that drinking alcohol while taking guanfacine may cause excessive drowsiness and sedation. They should also use caution while driving or using machinery because of the side effects of dizziness and/or drowsiness.
When hypertension is not controlled with a diuretic alone, guanfacine is usually not the drug of choice. Drugs such as beta blockers, calcium channel blockers, and angiotensin-converting enzyme inhibitors are preferred over guanfacine (Abramowicz, 1987a; Abramowicz, 1987b; Kastrup, 1988) .
TERAZOSIN HYDROCHLORIDE
Terazosin (Hytri n), an alpha-l blocker in oral tablet form, is used for the treatment of hypertension. It is ACE inhibitors are becoming the treatment of choice for newly diagnosed hypertension due to infrequent incidences of annoying side effects.
similar in action and effectiveness to its predecessor, prazosin (Minipress). Terazosin reduces peripheral vascular resistance by blocking sympathetic nerve impulses causing vasoconstriction, thereby reducing blood pressure. Since it has a long half-life, it is effectively administered on a once daily basis and can be used alone or in combination with other antihypertensives. The recommended dose range is 1 mg to 5 mg daily.
Clinical studies have shown terazosin not only has an antihypertensive effect, but also a slight hypocholesterolemic one as well. It has been demonstrated that total serum cholesterol falls during terazosin therapy.
The most commonly reported adverse reactions are headache, dizziness, asthenia, nasal congestion, and peripheral edema. Even though these side effects are not considered to be serious, they could potentially interfere with compliance.
The possibility of syncopal and orthostatic symptoms is associated with the first dose. Therefore, the first dose should be taken at bedtime and driving a car or any other hazardous activity should be avoided for 12 hours following the first dose. If the dose is increased or if therapy is resumed after an interruption of sev-eral days, a hypotensive response may occur. Sitting or lying down will usually reverse orthostatic hypotension (Kastrup, 1988; Luther, 1987; Tartaglione, 1987a) .
L1SINOPRIL HYDROCHLORIDE
Lisinopril (Zestril, Prinivil) is an angiotensin converting enzyme (ACE) inhibitor. This drug, available in oral tablet form, is used in the treatment of hypertension. ACE, which lisinopril inhibits, is responsible for converting angiotensin I to angiotensin II in vivo. The result is suppression of the renin-angiotensinaldosterone system and the lowering of both systolic and diastolic blood pressure due to a reduction in total peripheral resistance.
Lisinopril can be used with other antihypertensive agents or alone. The recommended starting dose is 10 mg daily in a single dose. The dose can be titrated according to the individual's response. The usual dose range is 20 mg-40 mg daily; however, up to 80 mg may be administered. Diuretics should be discontinued several days before the initial lisinopril dose to minimize the possibility of an exaggerated hypotensive response.
As with other ACE inhibitor drugs, lisinopril is usually well-tolerated. The most frequen t1y reported adverse effects are cough, dizziness, headache, fatigue, and diarrhea. Individuals with renal artery stenosis should have monitoring of therapy via renal function tests, such as serum creatinine and blood urea nitrogen, during the first few weeks of therapy. Because lisinopril acts by interfering with the renin-angiotensin system, hyperkalemia may result.
The drug can be taken with meals. It is probably best to avoid using salt substitutes (potassium chloride), since this may increase the risk of hyperkalemia. The employee should be told to report incidences of lightheaded ness or dizziness to the health care provider so the dosage may be promptly adjusted.
ACE inhibitors are becoming the treatment of choice for newly diagnosed hypertension due to i nfre-quent incidences of annoying side effects. This benefit may assist in drug therapy compliance (Kastrup, 1988) .
PENBUTOLOL SULFATE
Penbutolol (Levatol) sulfate is an antihypertensive in oral tablet form. It is a nonselective beta-adrenergic blocker that has a long half-life, allowing once daily dosing. This drug, though approved, has not yet been marketed (Kastrup, 1988) .
LOVASTATIN
Lovastatin (Mevacor), a cholesterol reducing drug in oral tablet form, is used to treat primary hypercholesterolemia in individuals who have not been able to lower their cholesterol by dietary means. Lovastatin therapy reduces blood levels of lowdensity lipoprotein cholesterol and total cholesterol. It acts by inhibiting HGM-CoA reductase, a necessary enzyme for biosynthesis of cholesterol. The person can expect either an increase or stability in the blood level of high-density lipoprotein (the so-called "good" cholesterol).
The person should first start on a cholesterol-lowering diet and continue on such a diet while taking lovastatin. The recommended starting dose is 20 mg daily, which may be increased up to 80 mg daily in divided doses or as a single dose. The maximum response to lovastatin is seen four to six weeks from initiation of therapy. Any necessary dose titrations should be made at that time.
The employee should be aware of the importance of regular hepatic enzyme tests every four to six weeks for the first 15 months of lovastatin therapy. Clinical studies have reported that a number of people (1. 9%) had increased levels of serum transaminase levels, which may suggest liver damage. In addition, the employee should have yearly eye exams to detect possible formation of cataracts or lens opacity. A number of people taking lovastatin developed lens opacities, which mayor may not be due to use of the drug.
Lastly, lovastatin should be discontinued in those who exhibit signs of Lovastatin may cause myositis when given concomitantly with immunosuppressive drugs or gemfibrozil (Abramowicz, 1987e; Kastrup, 1988) .
CIPROFLOXACIN HYDROCHLORIDE
Ciprofloxacin (Cipro) is the first broad spectrum fluoroquinoline antibiotic oral tablet for treatment of infections that normally require injectable antibiotic therapy. It interferes with DNA-gyrase, an enzyme required for DNA synthesis in bacteria. This bacteriocidal is effective against a wide range of gram negative and gram positive microorganisms, including Pseudomonas aeruginosa and
Staphylococcus aureus.
Ciprofloxacin is indicated for the treatment of lower respiratory tract infections, urinary tract infections, diarrheal infections, and infections located in the bones, joints, and skin. The recommended dosage, which depends on the severity of the infection and the infection site, ranges between 250 mg and 750 mg twice a day.
Ciprofloxacin should be used with Employees must understand the importance of complying with the prescribed doses for treatment to be effective. This drug's absorption is reduced when given with antacids containing aluminum or magnesium, which could result in lack of effectiveness. If the person is taking theophylline, an increased blood level of theophylline may occur. Therefore, blood levels should be monitored and theophylline dosage adjusted as necessary.
The employee should be made aware that ciprofloxacin may cause dizziness. This antibiotic may be taken with or without food. It is important to drink: plenty of fluids while on this drug. Since photosensitivity reactions have occurred, the employee should be advised to use a sunscreen if exposed to the sun for extended periods of time. Finally, antacids containing aluminum or magnesium should not be taken within two hours before/after taking ciprofloxacin (Abramowicz, 1987g; Kastrup, 1988) . CEFUROXIME AXETIL Cefuroxime (Ceftin), a cephalosporin, is administered in oral tablet form for the treatment of a variety of gram positive and gram negative bacterial infections. This broad-spectrum bacteriocidal is effective against a wide range of microorganisms, including many betalactamase-producing strains.
This drug is used for the treatment of pharyngitis, tonsilitis, otitis media, lower respiratory tract infections, and skin infections. The recommended dosage is 250 mg to 500 mg twice daily.
Cefuroxime, like other cephalosporins, should be used with caution in penicillin-sensitive clients since cross-sensitivity is possible. Cefuroxime is well-tolerated. The most frequent adverse reactions are nausea, diarrhea, vomiting, and vaginitis.
The employee should be aware that cefuroxime absorbs better when administered with food, although it is still effective when taken on an empty stomach (FDC Reports 1988; Kastrup, 1988) .
ZIDOVUDINE
This drug (Retrovir), formerly known as AZ'T, is an antiviral agent and the first effective treatment for Acquired Immune Deficiency Syndrome (AIDS). A1though this drug is not a cure, clinical studies have shown that it improves immune status and prolongs life.
Zidovudine is a thymidine analog that inhibits the replication of the virus responsible for causing AIDS, the human immunodeficiency virus (HIV-l). HIV-1 is a retrovirus that depends upon reverse transreplicase enzyme for its replication. The drug works by interfering with this enzyme and retarding or terminating growth of the virus. The initial dose is 200 mg every four hours. The drug is supplied in 100 mg capsules for oral intake.
The major toxicity related to zidovudine is bone marrow suppression, resulting in anemia, leukopenia, neutropenia, and thrombocytopenia. Anemia most commonly occurs four to six weeks after therapy begins and may require dose reduction, discontinuation of the drug, or blood transfusion(s). Blood counts should be performed every two weeks. Zidovudine may also cause headache, nausea, insomnia, gastrointestinal pain, and myalgias.
Concurrent administration of zidovudine with nephrotoxic drugs and drugs toxic to bone marrow may increase the risk of toxicity. Acetaminophen, aspirin, probenecid, or indomethacin may interfere with metabolism of zidovudine, which could increase toxicity. Ribavirin also interferes with effectiveness of zidovudine.
Employees taking zidovudine should be warned of the necessity for frequent blood counts. They should know the importance of eating foods rich in cyanocobalamin (vitamin B-12) and taking vitamin B-12supplements. Compliance with the medication schedule cannot be overemphasized. Keeping an alarm clock by the bedside can help accomplish this (Abramowicz, 1987f; FDC Reports, 1988; Gever, 1987; Kastrup, 1988; Tartaglione, 1987b) .
MUPIROCIN
Mupirocin (Bactroban) is a topical antibiotic that exerts its antimicrobial action by inhibiting RNA and protein synthesis. It is active against various strains of Staphylococcus and Streptococcus, bacteria responsible for most types of skin infections. It is especially useful in the treatment of impetigo. The drug does not alter normal skin flora or interfere with normal skin defense mechanisms.
Mupirocin should be applied topically to the skin two to three times daily for 5 to 14 days, or longer if necessary. If the' infection persists or becomes systemic, then systemic antibiotic therapy is needed.
The most commonly reported adverse reactions are local, such as burning, stinging, itching, and rash. No systemic toxicity or skin photosensitivity has been reported.
The employee should understand the importance ofcomplying with the prescribed multiple daily administrations of mupirocin for treatment to be effective. If the regimen is not followed, the health care provider may choose to prescribe a systemically administered drug (Kastrup, 1988; Parenti, 1987; Ward, 1986) .
MOMETASONE FUROATE
Mometasone (Elocon) is a synthetic topical corticosteroid used to treat corticosteroid-responsive dermatoses. Like other topical steroids, mometasone has anti-inflammatory, antipruritic, and vasoconstrictive properties. This drug is also used for conditions such as psoriasis and diaper rash. The recommended dose of the ointment or cream is a thin layer applied to the affected area daily.
Mometasone, when used for long periods of time, can be absorbed through the skin causing systemic effects, such as reversible hypothalamic-pituitary-adrenal suppression (HPA axis) or Cushing's syndrome. Therefore, occlusive dressings should not be placed over treated areas.
Mometasone is generally well-tolerated. The most common adverse reactions are burning, pruritis, irritation, dryness, and signs of skin atrophy.
The employee should be told not to cover treated areas with a bandage or other such occlusive cover, and to avoid eye/mouth contact with the medication (Abramowicz, 1987d; Kastrup, 1988) .
CARPROFEN
Carprofen (Rimadyl) is a nonsteroidal anti-inflammatory drug (NSAID), the safety ofwhich appears to be well documented. It inhibits prostaglandin synthetase and leukocyte migration. Carprofen is indicated for the treatment of various forms of arthritis, such as rheumatoid arthritis and osteoarthritis.
Carprofen is absorbed rapidly after oral administration. The usual dose is 300 mg daily. Food may hinder absorption.
Carprofen may inhibit renal prostaglandins and cause nephrotoxicity. It may be dangerous in people with a history of peptic ulcer disease, since prostaglandins protect the gastric mucosa. However, since carprofen has a weaker effect on prostaglandins than other drugs in this class, it is potentially safer for use.
Reported adverse reactions include rash, erythrerna, pruritis, and urticaria, all of which are mild and transient. Gastrointestinal disturbances may occur and some people experience hepatic enzyme elevations. Clinical hepatitis has not been reported as a problem.
Employees should be told to take this drug with a full glass of-water and on an empty stomach. Concomitant ingestion of alcohol or aspirin may increase the incidence of gastrointestinal disturbances (FDC Reports, 1988; Gever, 1987; O'Brien, 1987) .
FLUOXETINE
Fluoxetine (prozac) is an antidepressant that inhibits serotonin reuptake into the presynaptic terminal of neurons. This action also has an appetite suppressing effect.
Most people should be started on a 20 mg daily single dose. The dose range is 20 mg to 80 mg daily. The drug is well absorbed after oral administration. A significant decrease in depression occurs after one week of therapy, but maximal effect is not seen for approximately three weeks.
Adverse reactions associated with fluoxetine are usually mild and include nausea, headache, nervousness, anxiety, and insomnia. Dry mouth, drowsiness, sweating, diarrhea, and constipation have also been reported. Weight loss usually occurs, but rarely has therapy needed to be discontinued because of this effect. Most clinicians and clients look upon this side effect as fortuitous.
The employee should know not to expect instant results. A minimum of three weeks must pass before a determination of the drug's effectiveness can realistically be made (FDC Reports, 1988; Kastrup, 1988; Sommi, 1987) .
CONCLUSION
This review of pertinent new medications will alert the occupational health nurse to the drugs' indications, AAOHN Journa/1988; 36(10) : 425-430. 1.
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Many new drugs were introduced into the health care system in 1987.
The Federal Food and Drug Administration (FDA) approved 23 new drugs for marketing in the United States including anticholinergic, bronchodilator, antihypertensive, antibacterial, antihyperlipidemics, and anti-inflammatory agents.
The occupational health nurse plays a major role in the employees' health status. With current information on FDA drugs, the occupational health nurse can counsel appropriately and support employees' compliance endeavors.
Pathways to Excellence
The American Association of Occupational Health Nurses is the professional association for registered nurses who provide on-the-job health care for the nation's workers. AAOHN serves as an advocate for occupational health nursing, establishes standards of practice and assists the occupational health nurse in providing quality health care. AAOHN has approximately 170 local, state and regional constituent associations nationwide.
• The Profession -Occupational health nursing applies nursing principles to help workers achieve and maintain good health. This specialized practice is devoted to health promotion at the workplace based on prevention of illness and injury.
• The Association -To promote occupational health nursing, AAOHN has developed a variety of services including a monthly professional journal, a monthly newsletter, continuing education homestudy courses, a governmental lobbying program and an employment information service. 
